Skip to main content
  • Clinical Trials
Menu
Home
SPR
  • Healthcare Professionals
    • SPRINT® PNS System
      • Overview
      • Product Details
    • Clinical Evidence
    • Video Resources
    • Reimbursement
    • Education
    • Safety Information
    • MRI Safety Information
  • Patients & Caregivers
    • SPRINT® PNS System
      • Why SPRINT?
      • How It Works
      • What To Expect
      • Helpful FAQs
      • Safety Information
      • MRI Safety Information
    • Resources
      • Overview
      • Instructional Videos
      • Patient Stories
      • Recursos para pacientes
      • Clinical Evidence
  • About Us
    • About SPR
    • Leadership
    • Company Credo
  • News
  • Events
  • Careers
    • Overview
    • Job Listing
  • Contact Us

Press Releases

Breadcrumb

  1. Home
  2. Press Releases

All Press Releases

SPR News Placeholder SPR News Placeholder

Study of SPRINT PNS System demonstrates 12 months of low back pain relief following 60-day treatment

Press releases + media
study of post-amputation pain blog post thumbnail study of post-amputation pain blog post thumbnail

Study demonstrates 12-month relief of post-amputation pain following treatment with SPRINT PNS System

Press releases + media Research, data + publications
SPR Logo SPR Logo

SPR announces 1,000th SPRINT PNS procedure

Press releases + media
SPR News Placeholder SPR News Placeholder

DeviceTalks Q&A: Talking targeted pain management with CEO Maria Bennett

Press releases + media
SPR News Placeholder SPR News Placeholder

SPR's neuromodulation system treats phantom-limb pain

Press releases + media
SPR News Placeholder SPR News Placeholder

SPR Names Dr. Peter Staats as Chief Medical Advisor

Press releases + media
SPR News Placeholder SPR News Placeholder

SPR announces first use of SPRINT endura peripheral nerve stimulation system to treat complex regional pain syndrome

Press releases + media
SPR News Placeholder SPR News Placeholder

SPR awarded $10M from US Department of Defense

Press releases + media
SPR News Placeholder SPR News Placeholder

SPR announces first use of SPRINT extensa dual-lead peripheral nerve stimulation system to treat low back pain

Press releases + media
SPR News Placeholder SPR News Placeholder

FDA clears SPR's non-opioid SPRINT endura and extensa peripheral nerve stimulation systems for pain management

Press releases + media
SPR News Placeholder SPR News Placeholder

SPR secures $25 million in Series C financing

Press releases + media
SPR News Placeholder SPR News Placeholder

SPR promotes Dr. Joseph Boggs to SVP of research and development

Press releases + media

Pagination

  • Previous page ‹
  • Page1
  • Page2
  • Page3
  • Current page4
  • Page5
  • Next page ›
  • Healthcare Professionals
    • SPRINT® PNS System
      • Overview
      • Product Details
    • Clinical Evidence
    • Video Resources
    • Reimbursement
    • Education
    • Safety Information
    • MRI Safety Information
  • Patients & Caregivers
    • SPRINT® PNS System
      • Why SPRINT?
      • How It Works
      • What To Expect
      • Helpful FAQs
      • Safety Information
      • MRI Safety Information
    • Resources
      • Overview
      • Instructional Videos
      • Patient Stories
      • Recursos para pacientes
      • Clinical Evidence
  • About Us
    • About SPR
    • Leadership
    • Company Credo
  • News
  • Events
  • Careers
    • Overview
    • Job Listing
  • Contact Us
  • CPRA Requests
  • Consumer Health Data Request Form
  • Compliance
  • FCOI Policy
  • MRI Safety Information
  • Patent Information
  • Product Terms and Conditions
  • Safety Information
  • Trademarks
  • Billing Portal
Home
  • Consumer Health Data and Information Privacy Policy
  • Terms of Use
Visit us on Facebook
Visit us on Twitter
Visit us on Instagram
Visit us on YouTube
Visit us on LinkedIn

The SPRINT PNS System is indicated for up to 60 days for: (i) Symptomatic relief of chronic, intractable pain, post-surgical and post-traumatic acute pain; (ii) Symptomatic relief of post-traumatic pain; and (iii) Symptomatic relief of post-operative pain. The SPRINT PNS System is not intended to be placed in the region innervated by the cranial and facial nerves. Physicians should use their best judgment when deciding when to use the SPRINT PNS System. For more information see the SPRINT PNS System IFU. Most common adverse events are skin irritation and erythema. Results may vary. Rx only. 

View references for support of all claims.

Product and brand names/logos are registered or common law trademarks of SPR.

© 2025 SPR. All Rights Reserved.